These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37532611)

  • 21. Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
    Tricou V; Winkle PJ; Tharenos LM; Rauscher M; Escudero I; Hoffman E; LeFevre I; Borkowski A; Wallace D
    Vaccine; 2023 Nov; 41(47):6999-7006. PubMed ID: 37884415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
    Dayan GH; Thakur M; Boaz M; Johnson C
    Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.
    Kallás EG; Cintra MAT; Moreira JA; Patiño EG; Braga PE; Tenório JCV; Infante V; Palacios R; de Lacerda MVG; Batista Pereira D; da Fonseca AJ; Gurgel RQ; Coelho IC; Fontes CJF; Marques ETA; Romero GAS; Teixeira MM; Siqueira AM; Barral AMP; Boaventura VS; Ramos F; Elias Júnior E; Cassio de Moraes J; Covas DT; Kalil J; Precioso AR; Whitehead SS; Esteves-Jaramillo A; Shekar T; Lee JJ; Macey J; Kelner SG; Coller BG; Boulos FC; Nogueira ML
    N Engl J Med; 2024 Feb; 390(5):397-408. PubMed ID: 38294972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
    Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
    Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Tricou V; Yu D; Reynales H; Biswal S; Saez-Llorens X; Sirivichayakul C; Lopez P; Borja-Tabora C; Bravo L; Kosalaraksa P; Vargas LM; Alera MT; Rivera L; Watanaveeradej V; Dietze R; Fernando L; Wickramasinghe VP; Moreira ED; Fernando AD; Gunasekera D; Luz K; Oliveira AL; Tuboi S; Escudero I; Hutagalung Y; Lloyd E; Rauscher M; Zent O; Folschweiller N; LeFevre I; Espinoza F; Wallace D
    Lancet Glob Health; 2024 Feb; 12(2):e257-e270. PubMed ID: 38245116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
    Durbin AP; Whitehead SS; Shaffer D; Elwood D; Wanionek K; Thumar B; Blaney JE; Murphy BR; Schmidt AC
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1267. PubMed ID: 21829748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.
    Watanaveeradej V; Simasathien S; Nisalak A; Endy TP; Jarman RG; Innis BL; Thomas SJ; Gibbons RV; Hengprasert S; Samakoses R; Kerdpanich A; Vaughn DW; Putnak JR; Eckels KH; Barrera Rde L; Mammen MP
    Am J Trop Med Hyg; 2011 Aug; 85(2):341-51. PubMed ID: 21813857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Immunogenicity of an AS03
    Lin L; Lyke KE; Koren M; Jarman RG; Eckels KH; Lepine E; McArthur MA; Currier JR; Friberg H; Moris P; Keiser PB; De La Barrera R; Vaughn DW; Paris RM; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2020 Jul; 103(1):132-141. PubMed ID: 32342848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
    Tricou V; Essink B; Ervin JE; Turner M; Escudero I; Rauscher M; Brose M; Lefevre I; Borkowski A; Wallace D
    PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011124. PubMed ID: 36888687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
    Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
    Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Rivera IE; Kilbury J; Raanan M; Borkowski A; Papadimitriou A; Wallace D
    J Infect Dis; 2022 May; 225(9):1513-1520. PubMed ID: 32658250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City.
    Biswal S; Mendez Galvan JF; Macias Parra M; Galan-Herrera JF; Carrascal Rodriguez MB; Rodriguez Bueno EP; Brose M; Rauscher M; LeFevre I; Wallace D; Borkowski A
    Rev Panam Salud Publica; 2021; 45():e67. PubMed ID: 34131423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
    Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
    Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.
    Dayan GH; Garbes P; Noriega F; Izoton de Sadovsky AD; Rodrigues PM; Giuberti C; Dietze R
    Am J Trop Med Hyg; 2013 Dec; 89(6):1058-1065. PubMed ID: 24189367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
    Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
    PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.
    Tran NH; Chansinghakul D; Chong CY; Low CY; Shek LP; Luong CQ; Fargo C; Wartel TA; Sun S; Skipetrova A; Bouckenooghe A
    Hum Vaccin Immunother; 2019; 15(10):2315-2327. PubMed ID: 30724660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial.
    Turner M; Papadimitriou A; Winkle P; Segall N; Levin M; Doust M; Johnson C; Lucksinger G; Fierro C; Pickrell P; Raanan M; Tricou V; Borkowski A; Wallace D
    Hum Vaccin Immunother; 2020 Oct; 16(10):2456-2464. PubMed ID: 32119591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.